Frank Cole, MD
Internal Medicine · Fayetteville, GANPI 1568512549
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 20 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 13 manufacturers, the largest accounting for just 18.4% — the pattern of someone who eats at a lot of different presentations. That places this record below the midpoint for internal medicine clinicians in GA, where the typical reported total is $311.
Across 20 payments — averaging $20.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$75
- Boehringer Ingelheim$51
- Johnson & Johnson$40
- Lilly USA, LLC$39
- Abbott$39
- GSK$29
- plus $136 from 7 others
Across 615 payments — averaging $1093.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Alnylam Pharmaceuticals Inc.$282K
- Novartis$211K
- Astrazeneca UK Limited$154K
- AstraZeneca$13K
- Amgen$12K
What the payments were for
- Food & beverage$410100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 3 | $75 |
| Boehringer Ingelheim | 2 | $51 |
| Johnson & Johnson | 2 | $40 |
| Lilly USA, LLC | 2 | $39 |
| Abbott | 2 | $39 |
| GSK | 2 | $29 |
| Novartis | 1 | $25 |
| Merck | 1 | $24 |
| Medtronic | 1 | $22 |
| Sanofi-aventis U.S. LLC | 1 | $19 |
| Amgen | 1 | $18 |
| AbbVie | 1 | $14 |
| Seqirus USA Inc | 1 | $14 |
How this compares
$410 in reported general payments places this provider in the 50th percentile of 3,311 internal medicine providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 281 | $394,034 |
| EliquisApixaban | 167 | $212,667 |
| OzempicSemaglutide | 128 | $180,666 |
| XareltoRivaroxaban | 89 | $119,403 |
| MounjaroTirzepatide | 87 | $113,735 |
| JanuviaSitagliptin Phosphate | 75 | $92,469 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 72 | $73,602 |
| FarxigaDapagliflozin Propanediol | 56 | $69,199 |
| MyrbetriqMirabegron | 57 | $34,235 |
| TrulicityDulaglutide | 25 | $34,043 |
| Bydureon BciseExenatide Microspheres | 16 | $28,879 |
| LinzessLinaclotide | 31 | $26,492 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 29 | $25,029 |
| ProliaDenosumab | 11 | $19,025 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 28 | $17,964 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta | $51 | $405,099296 claims |
| Novo NordiskOzempic | $75 | $180,666128 claims |
| Lilly USA, LLCMounjaro, Trulicity | $39 | $147,778112 claims |
| Johnson & JohnsonXarelto, Invokana | $40 | $136,470110 claims |
| MerckJanuvia, Lagevrio (Eua) | $24 | $102,28486 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $19 | $73,60272 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $29 | $40,30857 claims |
| AbbVieLinzess, Synthroid | $14 | $33,528123 claims |
| AmgenProlia | $18 | $19,02511 claims |
| NovartisEntresto | $25 | $16,32412 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 3,311 internal medicine providers in Georgia.
Other internal medicine in Fayetteville
- Michael GibsonSmyrna$2.2M
- Eduard FatakhovAlpharetta$376K
- Tracey HenryAtlanta$305K
- Sharon TuckettVilla Rica$265K
- Ebon BourneMarietta$242K
- Jennifer WoehlerSavannah$207K
- Julian HutchinsGreensboro$201K
- Brian PearlmanDalton$199K
- Scott ParryAtlanta$162K
- Jennifer GilliganAtlanta$162K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.